AQR Capital Management LLC Has $34.21 Million Holdings in LivaNova PLC (NASDAQ:LIVN)

AQR Capital Management LLC raised its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 79.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 742,180 shares of the company's stock after acquiring an additional 328,313 shares during the quarter. AQR Capital Management LLC owned approximately 1.37% of LivaNova worth $34,214,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Central Pacific Bank Trust Division grew its stake in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after buying an additional 720 shares during the period. Nordea Investment Management AB grew its holdings in shares of LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after purchasing an additional 12,470 shares during the period. Diversified Trust Co raised its holdings in LivaNova by 9.5% in the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company's stock valued at $761,000 after buying an additional 1,425 shares during the period. Harbor Capital Advisors Inc. acquired a new position in LivaNova in the fourth quarter valued at about $1,954,000. Finally, KBC Group NV raised its stake in shares of LivaNova by 130.5% in the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after acquiring an additional 56,580 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of research reports. Mizuho dropped their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research note on Monday, March 17th. The Goldman Sachs Group cut their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Finally, StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $59.33.

LivaNova Stock Performance

LivaNova stock traded up $0.63 during mid-day trading on Thursday, reaching $44.13. The company had a trading volume of 451,139 shares, compared to its average volume of 629,941. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a 50 day moving average of $37.79 and a 200-day moving average of $45.33. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $63.57. The firm has a market cap of $2.41 billion, a price-to-earnings ratio of 104.87 and a beta of 0.84.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.